[go: up one dir, main page]

AR098168A1 - Formulación estable de insulina glulisina - Google Patents

Formulación estable de insulina glulisina

Info

Publication number
AR098168A1
AR098168A1 ARP140103985A ARP140103985A AR098168A1 AR 098168 A1 AR098168 A1 AR 098168A1 AR P140103985 A ARP140103985 A AR P140103985A AR P140103985 A ARP140103985 A AR P140103985A AR 098168 A1 AR098168 A1 AR 098168A1
Authority
AR
Argentina
Prior art keywords
stable formulation
glulisine insulin
glulisine
insulin
pharmaceutical formulation
Prior art date
Application number
ARP140103985A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49552301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR098168(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR098168A1 publication Critical patent/AR098168A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación farmacéutica acuosa que comprende 200 - 1000 U/mL de insulina glulisina. Reivindicación 8: La formulación farmacéutica acuosa de la reivindicación 7, en la que la sustancia tampón es trometamol.
ARP140103985A 2013-10-25 2014-10-23 Formulación estable de insulina glulisina AR098168A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306475 2013-10-25

Publications (1)

Publication Number Publication Date
AR098168A1 true AR098168A1 (es) 2016-05-04

Family

ID=49552301

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103985A AR098168A1 (es) 2013-10-25 2014-10-23 Formulación estable de insulina glulisina

Country Status (18)

Country Link
US (2) US20150119323A1 (es)
EP (1) EP3060240A1 (es)
JP (1) JP6525987B2 (es)
KR (1) KR20160074562A (es)
CN (1) CN105705161A (es)
AR (1) AR098168A1 (es)
AU (1) AU2014338863A1 (es)
BR (1) BR112016008736A2 (es)
CA (1) CA2928320A1 (es)
CL (1) CL2016000950A1 (es)
HK (1) HK1225613A1 (es)
IL (1) IL245109A0 (es)
MX (1) MX2016005395A (es)
PH (1) PH12016500720A1 (es)
RU (1) RU2691059C2 (es)
SG (2) SG11201602939QA (es)
TW (1) TW201605489A (es)
WO (1) WO2015059302A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087081A2 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue insulinderivate mit extrem verzögertem zeit-/wirkungsprofil
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
ES2965209T3 (es) 2009-11-13 2024-04-11 Sanofi Aventis Deutschland Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
JP7145849B2 (ja) 2016-09-29 2022-10-03 アレコル リミテッド 新規の製剤
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
AR131148A1 (es) * 2022-11-26 2025-02-19 Obshchestvo S Ogranichennoy Otvetstvennostyu «Geropharm» Composiciones de insulina de acción rápida (variantes de las mismas)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
JP5841708B2 (ja) * 2008-07-01 2016-01-13 日東電工株式会社 表面被覆微粒子の医薬組成物
PH12011502708B1 (en) * 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
CN102548583B (zh) * 2009-07-31 2015-04-22 赛诺菲-安万特德国有限公司 包含胰岛素连接物缀合物的前药
KR101836070B1 (ko) * 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
US9993529B2 (en) * 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EA201400031A1 (ru) * 2011-06-17 2014-07-30 Галозим, Инк. Стабильные составы на основе фермента, разрушающего хиалуронан
DK2919804T3 (en) * 2012-11-13 2018-05-14 Adocia Rapidly acting insulin formulation comprising a substituted anionic compound
CN114939156A (zh) * 2014-01-09 2022-08-26 赛诺菲 门冬胰岛素的稳定化药物制剂

Also Published As

Publication number Publication date
US20150119323A1 (en) 2015-04-30
RU2016119746A3 (es) 2018-06-04
CL2016000950A1 (es) 2016-11-04
IL245109A0 (en) 2016-06-30
SG11201602939QA (en) 2016-05-30
PH12016500720A1 (en) 2016-05-30
RU2691059C2 (ru) 2019-06-10
EP3060240A1 (en) 2016-08-31
US20180036411A1 (en) 2018-02-08
AU2014338863A1 (en) 2016-05-19
JP2016539921A (ja) 2016-12-22
JP6525987B2 (ja) 2019-06-05
CA2928320A1 (en) 2015-04-30
RU2016119746A (ru) 2017-11-30
MX2016005395A (es) 2017-02-28
TW201605489A (zh) 2016-02-16
WO2015059302A1 (en) 2015-04-30
KR20160074562A (ko) 2016-06-28
HK1225613A1 (zh) 2017-09-15
SG10201803430SA (en) 2018-06-28
BR112016008736A2 (pt) 2017-09-12
CN105705161A (zh) 2016-06-22

Similar Documents

Publication Publication Date Title
AR098168A1 (es) Formulación estable de insulina glulisina
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CO6680609A2 (es) Composición acuosa que contiene bromhexina
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
UY35306A (es) Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina.
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
EP3009426A4 (en) 4-ALKYNYL-IMIDAZOLE DERIVATIVE AND MEDICAMENT THEREFORE AS AN ACTIVE SUBSTANCE
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
CL2015003738A1 (es) Formulación líquida estable de amg-416 (velcalcetida)
MX2017009827A (es) Formulacion farmaceutica.
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
MX388400B (es) Una composición de dos componentes, que comprende ácido acetilsalicílico.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica

Legal Events

Date Code Title Description
FB Suspension of granting procedure